-
Amara R R, Smith J M, Staprans S I. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine[J]. J Virol, 2002, 76(12): 6138-6146. doi: 10.1128/JVI.76.12.6138-6146.2002
-
Binley J M, Wrin T, Korber B. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies[J]. J Virol, 2004, 78(23): 13232-13252. doi: 10.1128/JVI.78.23.13232-13252.2004
-
Bolmstedt A, Hinkula J, Rowcliffe E. Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosy-lation signals. Effects of elimination of the V3 N306 glycan[J]. Vaccine, 2001, 20(3-4): 397-405. doi: 10.1016/S0264-410X(01)00358-9
-
Burton D R, Desrosiers R C, Doms R W. HIV vaccine design and the neutralizing antibody problem[J]. Nat Immunol, 2004, 5(3): 233-236. doi: 10.1038/ni0304-233
-
Cao J, Sullivan N, Desjardin E. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein[J]. J Virol, 1997, 71(12): 9808-9812.
-
Dhillon A K, Donners H, Pantophlet R. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors[J]. J Virol, 2007, 81(12): 6548-6562. doi: 10.1128/JVI.02749-06
-
Dimitrov D S. Cell biology of virus entry[J]. Cell, 2000, 101(7): 697-702. doi: 10.1016/S0092-8674(00)80882-X
-
Doms R W. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection[J]. Virology, 2000, 276(2): 229-237. doi: 10.1006/viro.2000.0612
-
Dunfee R L, Thomas E R, Wang J. Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia[J]. Virology, 2007, 367(1): 222-234. doi: 10.1016/j.virol.2007.05.029
-
Edwards T G, Hoffman T L, Baribaud F. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein[J]. J Virol, 2001, 75(11): 5230-5239. doi: 10.1128/JVI.75.11.5230-5239.2001
-
Evans D T, O'Connor D H, Jing P. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef[J]. Nat Med, 1999, 5(11): 1270-1276. doi: 10.1038/15224
-
Fenyo E M, Putkonen P. Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections[J]. Immunol Lett, 1996, 51(1-2): 95-99. doi: 10.1016/0165-2478(96)02561-8
-
Grundner C, Mirzabekov T, Sodroski J. Solid-phase proteoliposomes containing human immuno-deficiency virus envelope glycoproteins[J]. J Virol, 2002, 76(7): 3511-3521. doi: 10.1128/JVI.76.7.3511-3521.2002
-
Gzyl J, Bolesta E, Wierzbicki A. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses[J]. Virology, 2004, 318(2): 493-506. doi: 10.1016/j.virol.2003.10.009
-
Hemsley A, Arnheim N, Toney M D. A simple method for site-directed mutagenesis using the polymerase chain reaction[J]. Nucleic Acids Res, 1989, 17(16): 6545-6551. doi: 10.1093/nar/17.16.6545
-
Hogg R S, Yip B, Kully C. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens[J]. CMA, 1999, 160(5): 659-665.
-
Jeffs S A, Gorny M K, Williams C. Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120[J]. Immunol Lett, 2001, 79(3): 209-213. doi: 10.1016/S0165-2478(01)00289-9
-
Kang S M, Quan F S, Huang C. Modified HIV envelope proteins with enhanced binding to neut-ralizing monoclonal antibodies[J]. Virology, 2005, 331(1): 20-32. doi: 10.1016/j.virol.2004.10.005
-
Kim Y B, Han D P, Cao C. Immunogenicity and ability of variable loop-deleted human immunodefi-ciency virus type 1 envelope glycoproteins to elicit neutra-lizing antibodies[J]. Virology, 2003, 305(1): 124-137. doi: 10.1006/viro.2002.1727
-
Kwong P D, Doyle M L, Casper D J. HIV-1 evades antibody-mediated neutralization through confor-mational masking of receptor-binding sites[J]. Nature, 2002, 420(6916): 678-682. doi: 10.1038/nature01188
-
Kwong P D, Wyatt R, Robinson J. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody[J]. Nature, 1998, 393(6686): 648-659. doi: 10.1038/31405
-
Moulard M, Phogat S K, Shu Y. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes[J]. Proc Natl Acad Sci USA, 2002, 99(10): 6913-6918. doi: 10.1073/pnas.102562599
-
Pantophlet R, Ollmann S E, Poignard P. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120[J]. J Virol, 2003, 77(1): 642-658. doi: 10.1128/JVI.77.1.642-658.2003
-
Parren P W, Moore J P, Burton D R. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity[J]. AIDS, 1999, 13 Suppl A(): S137-S162.
-
Quan F S, Sailaja G, Skountzou I. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins[J]. Vaccine, 2007, 25(19): 3841-3850. doi: 10.1016/j.vaccine.2007.01.107
-
Sanders R W, Venturi M, Schiffner L. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120[J]. J Virol, 2002, 76(14): 7293-7305. doi: 10.1128/JVI.76.14.7293-7305.2002
-
Weiner M P, Costa G L. Rapid PCR site-directed mutagenesis[J]. PCR Methods Appl, 1994, 4(3): S131-S136. doi: 10.1101/gr.4.3.S131
-
Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers[J]. J Virol, 2001, 75(3): 1165-1171. doi: 10.1128/JVI.75.3.1165-1171.2001
-
Yang Z Y, Chakrabarti B K, Xu L. Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope[J]. J Virol, 2004, 78(8): 4029-4036. doi: 10.1128/JVI.78.8.4029-4036.2004
-
Zwick M B, Labrijn A F, Wang M. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41[J]. J Virol, 2001, 75(22): 10892-10905. doi: 10.1128/JVI.75.22.10892-10905.2001